Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WI Harper Closes $175 Million Venture Fund for US-Asia Investments

publication date: May 18, 2016
WI Harper Group, an early investor in China and other Asian countries, closed WIH Fund VIII LP, which was over-subscribed at $175 million. WI Harper describes itself as an early stage venture capital firm focused on US-Asia cross-border opportunities. Although the company specializes in TMT investments, it also has supported life science companies. In the sector, the company will emphasize healthcare services including both clinical and digital health, innovative medical devices and diagnostics, as well as therapeutic discovery and development companies. More details...

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital